ArticleFrontiers in aging neuroscience2022
Investigating the Impact of Environment and Data Aggregation by Walking Bout Duration on Parkinson's Disease Classification Using Machine Learning.
Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Wearable Sensors in Gait Assessment for Parkinson Disease and Stroke in Real-World Environments: Systematic Review and Meta-Analysis.Journal of medical Internet research · 2026Pooled it
- Real-world gait study of Parkinson's disease using wearable sensors: a systematic review.Journal of neuroengineering and rehabilitation · 2026Pooled it
- Construct validity of instrumented gait assessments in hospital and daily life mobility in patients with Parkinson's disease and atypical Parkinson's syndromes: an exploratory study.Journal of neurology · 2026Trial
- Systemic Inflammation Triggers Motor Axon Degeneration Via Macrophage IL-1β-Mediated P53/SIRT1/Autophagy Pathway.Inflammation · 2026Article
- Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational study.Scientific reports · 2026Observational
- Moving beyond the hospital: in-depth characterization of daily-life mobility in patients with atypical Parkinsonian disorders.NPJ Parkinson's disease · 2026Article
- A systematic review of real-world gait-related digital mobility outcomes in Parkinson's disease.NPJ digital medicine · 2025Article
- Capture of Longitudinal Change in Real-Life Walking in Cerebellar Ataxia Increases Patient Relevance and Effect Size.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Cognition and Activity of Daily Living Function in people with Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device.Scientific reports · 2024Article
- Complexities and challenges of translating intervention success to real world gait in people with Parkinson's disease.Frontiers in neurology · 2024Review
- Laboratory and free-living gait performance in adults with COPD and healthy controls.ERJ open research · 2023Article
- Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium.Journal of neuroengineering and rehabilitation · 2023Article
- Gait and turning characteristics from daily life increase ability to predict future falls in people with Parkinson's disease.Frontiers in neurology · 2023Article
- Personalised Gait Recognition for People with Neurological Conditions.Sensors (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Parkinson's disease (PD) is a common neurodegenerative disease. PD misdiagnosis can occur in early stages. Gait impairment in PD is typical and is linked with an increased fall risk and poorer quality of life. Applying machine learning (ML) models to real-world gait has the potential to be more sensitive to classify PD compared to laboratory data. Real-world gait yields multiple walking bouts (WBs), and selecting the optimal method to aggregate the data (e.g., different WB durations) is essential as this may influence classification performance. The objective of this study was to investigate the impact of environment (laboratory vs. real world) and data aggregation on ML performance for optimizing sensitivity of PD classification. Gait assessment was performed on 47 people with PD (age: 68 ± 9 years) and 52 controls [Healthy controls (HCs), age: 70 ± 7 years]. In the laboratory, participants walked at their normal pace for 2 min, while in the real world, participants were assessed over 7 days. In both environments, 14 gait characteristics were evaluated from one tri-axial accelerometer attached to the lower back. The ability of individual gait characteristics to differentiate PD from HC was evaluated using the Area Under the Curve (AUC). ML models (i.e., support vector machine, random forest, and ensemble models) applied to real-world gait showed better classification performance compared to laboratory data. Real-world gait characteristics aggregated over longer WBs (WB 30-60 s, WB > 60 s, WB > 120 s) resulted in superior discriminative performance (PD vs. HC) compared to laboratory gait characteristics (0.51 ≤ AUC ≤ 0.77). Real-world gait speed showed the highest AUC of 0.77. Overall, random forest trained on 14 gait characteristics aggregated over WBs > 60 s gave better performance (F1 score = 77.20 ± 5.51%) as compared to laboratory results (F1 Score = 68.75 ± 12.80%). Findings from this study suggest that the choice of environment and data aggregation are important to achieve maximum discrimination performance and have direct impact on ML performance for PD classification. This study highlights the importance of a harmonized approach to data analysis in order to drive future implementation and clinical use. Clinical Trial Registration: [09/H0906/82].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.